SCHEMBL2805588

SCHEMBL2805588

O=C(NCCc1cccs1)N1CCc2c(cnc3[nH]ncc23)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 2/20 0.49
CHEK1 O14757 1/20 0.49
DAPK3 O43293 1/20 0.49
MAP4K4 O95819 1/20 0.49
PIM1 P11309 1/20 0.49
PRKACA P17612 1/20 0.49
KDR P35968 1/20 0.49
MAP2K2 P36507 1/20 0.49
MAPK8 P45983 1/20 0.49
CSNK1A1 P48729 1/20 0.49
CDK8 P49336 1/20 0.49
CLK2 P49760 1/20 0.49
GSK3B P49841 1/20 0.49
CDK7 P50613 1/20 0.49
CDK9 P50750 1/20 0.49
PRKX P51817 1/20 0.49
CDK5 Q00535 1/20 0.49
MAP2K1 Q02750 1/20 0.49
ACVR1 Q04771 1/20 0.49
MST1R Q04912 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2804990 0.84 NAMPT (0.46) NAMPTNPC1SMN1; SMN2ALDH1A1
SCHEMBL2805762 0.82 NAMPT (0.46) NAMPTCASP3HSD11B1ALDH1A1
SCHEMBL2805431 0.81 KMT2A (0.46) ROCK1NAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL2804250 0.81 KMT2A (0.41) CHEK1NAMPTLMNAALDH1A1
SCHEMBL2806964 0.77 HSD11B1 (0.37) ROCK1CHEK1DAPK3MAP4K4PIM1
SCHEMBL2803239 0.77 PRMT5 (0.38) NAMPTCYP1A2
SCHEMBL13273857 0.77 KMT2A (0.34) CHEK1NAMPT
SCHEMBL2802871 0.76 LMNA (0.52) NAMPTNPC1RAB9ALMNAALDH1A1
SCHEMBL2809081 0.76 KMT2A (0.43) SMN1; SMN2ROCK2LMNAALDH1A1
SCHEMBL2804632 0.76 NAMPT (0.44) CLK2CLK4NAMPTNPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 ROCK1 1929/4885CHEK1 476/4885DAPK3 853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.